Abstract
Asparaginase is a mainstay of treatment of childhood acute lymphoblastic leukemia. Pegylation of asparaginase extends its biological half-life and has been introduced in the newest treatment protocols aiming to further increase treatment success. Hyperammonemia is a recognized side effect of asparaginase treatment, but little is known about its incidence and clinical relevance. Alerted by a patient with severe hyperammonemia after introduction of the new acute lymphoblastic leukemia protocol, we analyzed blood samples and clinical data of eight consecutive patients receiving pegylated asparaginase (PEG-asparaginase) during their treatment of acute lymphoblastic leukemia. All patients showed hyperammonemia (>50 μmol/L) and seven patients (88 %) showed ammonia concentrations > 100 μmol/L. Maximum ammonia concentrations ranged from 89 to 400 μmol/L. Symptoms varied from mild anorexia and nausea to headache, vomiting, dizziness, and lethargy and led to early interruption of PEG-asparaginase in three patients. No evidence of urea cycle malfunction was found, so overproduction of ammonia through hydrolysis of plasma asparagine and glutamine seems to be the main cause. Interestingly, ammonia concentrations correlated with triglyceride values (r = 0.68, p < 0.0001), suggesting increased overall toxicity.
The prolonged half-life of PEG-asparaginase may be responsible for the high incidence of hyperammonemia and warrants future studies to define optimal dosing schedules based on ammonia concentrations and individual asparagine and asparaginase measurements.
Both last authors contributed equally
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Alvarez OA, Zimmerman G (2000) Pegaspargase-induced pancreatitis. Med Pediatr Oncol 34:200–205
Asselin BL, Whitin JC, Coppola DJ, Rupp IP, Sallan SE, Cohen HJ (1993) Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol 11:1780–1786
Cohn RM, Roth KS (2004) Hyperammonemia, bane of the brain. Clin Pediatr (Phila) 43:683–689
Earl M (2009) Incidence and management of asparaginase-associated adverse events in patients with acute lymphoblastic leukemia. Clin Adv Hematol Oncol 7:600–606
Jorck C, Kiess W, Weigel JF, Mutze U, Bierbach U, Beblo S (2011) Transient hyperammonemia due to l-asparaginase therapy in children with acute lymphoblastic leukemia or non-Hodgkin lymphoma. Pediatr Hematol Oncol 28:3–9
Kamps WA, van der Pal-de Bruin KM, Veerman AJ, Fiocco M, Bierings M, Pieters R (2010) Long-term results of Dutch Childhood Oncology Group studies for children with acute lymphoblastic leukemia from 1984 to 2004. Leukemia 24:309–319
Laterza OF, Gerhardt G, Sokoll LJ (2003) Measurement of plasma ammonia is affected in patients receiving asparaginase therapy. Clin Chem 49:1710–1711
Leonard JV, Kay JD (1986) Acute encephalopathy and hyperammonaemia complicating treatment of acute lymphoblastic leukaemia with asparaginase. Lancet 1:162–163
Lockwood AH, McDonald JM, Reiman RE, Gelbard AS, Laughlin JS, Duffy TE, Plum F (1979) The dynamics of ammonia metabolism in man. Effects of liver disease and hyperammonemia. J Clin Invest 63:449–460
Muller HJ, Boos J (1998) Use of l-asparaginase in childhood ALL. Crit Rev Oncol Hematol 28:97–113
Prager MD, Bachynsky N (1968) Asparagine synthetase in normal and malignant tissues: correlation with tumor sensitivity to asparaginase. Arch Biochem Biophys 127:645–654
Rytting M (2010) Peg-asparaginase for acute lymphoblastic leukemia. Expert Opin Biol Ther 10:833–839
Steiner M, Attarbaschi A, Kastner U, Dworzak M, Haas OA, Gadner H, Mann G (2007) Distinct fluctuations of ammonia levels during asparaginase therapy for childhood acute leukemia. Pediatr Blood Cancer 49:640–642
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Additional information
Communicated by: Claude Bachmann
Appendices
Take Home Message
Pegylation of asparaginase, used in the treatment of childhood acute lymphoblastic leukemia, seems to result in a high incidence of symptomatic hyperammonemia due to its prolonged half-life.
Authorship and Disclosures
KH designed the research, collected and analyzed data, and wrote the chapter. BP performed and analyzed laboratory studies and revised the manuscript critically. TK revised the manuscript critically. PH designed the research, analyzed data, and wrote the chapter. MB designed the research, analyzed data, and wrote the chapter. The authors declare no conflict of interest.
Rights and permissions
Copyright information
© 2012 SSIEM and Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Heitink-Pollé, K.M.J., Prinsen, B.H.C.M.T., de Koning, T.J., van Hasselt, P.M., Bierings, M.B. (2012). High Incidence of Symptomatic Hyperammonemia in Children with Acute Lymphoblastic Leukemia Receiving Pegylated Asparaginase. In: Brown, G., Morava, E., Peters, V., Gibson, K., Zschocke, J. (eds) JIMD Reports - Case and Research Reports, 2012/4. JIMD Reports, vol 7. Springer, Berlin, Heidelberg. https://doi.org/10.1007/8904_2012_156
Download citation
DOI: https://doi.org/10.1007/8904_2012_156
Received:
Revised:
Accepted:
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-32441-3
Online ISBN: 978-3-642-32442-0
eBook Packages: MedicineMedicine (R0)